Literature DB >> 12934066

Body language: the function of PML nuclear bodies in apoptosis regulation.

T G Hofmann1, H Will.   

Abstract

Promyelocytic leukaemia (PML) nuclear bodies (NBs) are macromolecular nuclear domains present in virtually every mammalian cell. PML nuclear bodies (PML-NBs) were functionally linked to various fundamental cellular processes, including transcriptional control, tumour suppression and apoptosis regulation. Supporting the important function of PML and its associated NBs in apoptosis regulation, several apoptotic regulators localise to PML-NBs, and cells from PML-deficient mice show severe apoptotic defects, including induction of genotoxic stress and death receptor CD95 (Fas/APO-1) activation. Based on the current literature, we hypothesise that PML-NBs regulate apoptosis through different molecular mechanisms, on the one hand by acting as macromolecular scaffolds for recruitment and post-translational modification of the apoptotic key regulator p53, and on the other by regulating the subcellular bioavailability and quality of some apoptotic signal transducers. Published online 22 August 2003

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12934066     DOI: 10.1038/sj.cdd.4401313

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  51 in total

Review 1.  The DNA damage-induced cell death response: a roadmap to kill cancer cells.

Authors:  Sonja Matt; Thomas G Hofmann
Journal:  Cell Mol Life Sci       Date:  2016-01-20       Impact factor: 9.261

2.  SUMO conjugation to the matrix attachment region-binding protein, special AT-rich sequence-binding protein-1 (SATB1), targets SATB1 to promyelocytic nuclear bodies where it undergoes caspase cleavage.

Authors:  Joseph-Anthony T Tan; Yujie Sun; Jing Song; Yuan Chen; Theodore G Krontiris; Linda K Durrin
Journal:  J Biol Chem       Date:  2008-04-11       Impact factor: 5.157

3.  Ipr1 gene mediates innate immunity to tuberculosis.

Authors:  Hui Pan; Bo-Shiun Yan; Mauricio Rojas; Yuriy V Shebzukhov; Hongwei Zhou; Lester Kobzik; Darren E Higgins; Mark J Daly; Barry R Bloom; Igor Kramnik
Journal:  Nature       Date:  2005-04-07       Impact factor: 49.962

4.  Coordinated regulation of p53 apoptotic targets BAX and PUMA by SMAR1 through an identical MAR element.

Authors:  Surajit Sinha; Sunil Kumar Malonia; Smriti P K Mittal; Kamini Singh; Sreenath Kadreppa; Rohan Kamat; Robin Mukhopadhyaya; Jayanta K Pal; Samit Chattopadhyay
Journal:  EMBO J       Date:  2010-01-14       Impact factor: 11.598

5.  PML: An emerging tumor suppressor and a target with therapeutic potential.

Authors:  Erin L Reineke; Hung-Ying Kao
Journal:  Cancer Ther       Date:  2009-09-01

6.  The adenoviral oncogene E1A-13S interacts with a specific isoform of the tumor suppressor PML to enhance viral transcription.

Authors:  Julia Berscheminski; Peter Groitl; Thomas Dobner; Peter Wimmer; Sabrina Schreiner
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

Review 7.  Hepatitis C-associated liver carcinogenesis: role of PML nuclear bodies.

Authors:  Kerstin Herzer; Guido Gerken; Thomas G Hofmann
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

8.  Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense.

Authors:  Mathieu Pampin; Yannick Simonin; Bruno Blondel; Yann Percherancier; Mounira K Chelbi-Alix
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

9.  Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance.

Authors:  Wei-Wei Pan; Jian-Jie Zhou; Xiao-Man Liu; Ying Xu; Lian-Jun Guo; Chao Yu; Qing-Hua Shi; Heng-Yu Fan
Journal:  J Biol Chem       Date:  2013-03-28       Impact factor: 5.157

10.  Herpesvirus protein ICP27 switches PML isoform by altering mRNA splicing.

Authors:  Takayuki Nojima; Takako Oshiro-Ideue; Hiroto Nakanoya; Hidenobu Kawamura; Tomomi Morimoto; Yasushi Kawaguchi; Naoyuki Kataoka; Masatoshi Hagiwara
Journal:  Nucleic Acids Res       Date:  2009-09-03       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.